Enasidenib

Introduction: What is Enasidenib?

Enasidenib is a targeted therapy medication primarily used in the treatment of certain types of blood cancers, specifically acute myeloid leukemia (AML). It is classified as an isocitrate dehydrogenase-2 (IDH2) inhibitor, which means it works by blocking the activity of the mutated IDH2 enzyme that contributes to the growth of cancer cells. By inhibiting this enzyme, Enasidenib helps to restore normal cell function and promote the differentiation of immature blood cells into healthy ones.

Uses of Enasidenib

Enasidenib is approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific mutation in the IDH2 gene. This mutation is found in a subset of AML patients. Enasidenib is used when other treatments have failed or when patients are not candidates for intensive chemotherapy.

How It Works

Enasidenib works by targeting and inhibiting the mutated IDH2 enzyme. In normal cells, IDH2 helps convert isocitrate to alpha-ketoglutarate, a process essential for cellular metabolism. However, in cancer cells with the IDH2 mutation, this process is disrupted, leading to the accumulation of a metabolite called 2-hydroxyglutarate (2-HG), which promotes cancer cell growth. By inhibiting the mutated enzyme, Enasidenib reduces the levels of 2HG, allowing the cancer cells to mature and die off, thereby slowing down or stopping the progression of the disease.

Dosage and Administration

Enasidenib is administered orally in the form of a tablet. The standard adult dosage is typically 100 mg taken once daily. It is important for patients to take the medication at the same time each day to maintain consistent levels in the body. The dosage may be adjusted based on the patient's response to treatment and any side effects experienced. Pediatric use has not been established, and therefore, it is not recommended for children.

Side Effects of Enasidenib

Like all medications, Enasidenib can cause side effects. Common side effects include:

• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Loss of appetite
• Elevated liver enzymes

Serious side effects may include:

• Differentiation syndrome (a potentially life-threatening condition characterized by fever, difficulty breathing, and fluid retention)
• Liver problems (hepatotoxicity)
• Infections due to low blood cell counts

Patients should report any severe or unusual symptoms to their healthcare provider immediately.

Drug Interactions

Enasidenib can interact with several medications, which may affect how it works or increase the risk of side effects. Major drug interactions include:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase Enasidenib levels in the blood.
• Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort) may decrease its effectiveness.
• Other medications that affect liver enzymes should be used with caution.

Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Benefits of Enasidenib

The primary benefit of Enasidenib is its targeted approach to treating AML with the IDH2 mutation. This specificity can lead to:

• Improved response rates in patients with this mutation.
• A different side effect profile compared to traditional chemotherapy, potentially leading to better tolerability.
• The possibility of achieving remission in patients who have not responded to other treatments.

Contraindications of Enasidenib

Enasidenib should be avoided in certain populations, including:

• Pregnant or breastfeeding women, as it may harm the fetus or infant.
• Use with caution in patients with severe hepatic impairment.
• Individuals with a known hypersensitivity to Enasidenib or any of its components.

Precautions and Warnings

Before starting Enasidenib, patients should undergo laboratory tests to assess liver function and blood cell counts. Regular monitoring is essential during treatment to detect any potential side effects early. Patients should also be aware of the signs of differentiation syndrome and seek immediate medical attention if they experience symptoms such as fever, difficulty breathing, or swelling.

FAQs

What is Enasidenib used for?

Enasidenib is used to treat adults with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation.

How is Enasidenib taken?

Enasidenib is taken orally as a tablet, usually 100 mg once daily.

What are the common side effects?

Common side effects include nausea, vomiting, diarrhea, fatigue, and loss of appetite.

Can Enasidenib be taken with other medications?

Some medications can interact with Enasidenib. Always inform your doctor about all medications you are taking.

Is Enasidenib safe during pregnancy?

No, Enasidenib is not recommended during pregnancy due to potential harm to the fetus.

What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember. If it's close to the next dose, skip the missed dose and continue with your regular schedule.

How long will I need to take Enasidenib?

Treatment duration varies based on individual response and side effects. Your doctor will determine the best plan for you.

What is differentiation syndrome?

Differentiation syndrome is a serious condition that can occur during treatment, characterized by fever, difficulty breathing, and fluid retention.

Can I drink alcohol while taking Enasidenib?

It is advisable to limit alcohol consumption, as it may increase the risk of liver problems.

How often will I need checks?

Regular checks are necessary to monitor your response to treatment and manage any side effects. Your doctor will schedule these visits.

Brand Names

Enasidenib is marketed under the brand name Idhifa.

Conclusion

Enasidenib represents a significant advancement in the treatment of acute myeloid leukemia, particularly for patients with the IDH2 mutation. Its targeted mechanism of action offers a new option for those who have not responded to traditional therapies. While it has potential side effects and interactions, its benefits in improving patient outcomes make it a valuable addition to cancer treatment options.